Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.
Viruses
; 16(7)2024 Jul 05.
Article
in En
| MEDLINE
| ID: mdl-39066247
ABSTRACT
Despite the significant progress made, CMV infection is one of the most frequent infectious complications in transplant recipients. CMV infections that become refractory or resistant (R/R) to the available antiviral drugs constitute a clinical challenge and are associated with increased morbidity and mortality. Novel anti-CMV therapies have been recently developed and introduced in clinical practice, which may improve the treatment of these infections. In this review, we summarize the treatment options for R/R CMV infections in adult hematopoietic cell transplant and solid organ transplant recipients, with a special focus on newly available antiviral agents with anti-CMV activity, including maribavir and letermovir.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Cytomegalovirus Infections
/
Cytomegalovirus
/
Drug Resistance, Viral
/
Transplant Recipients
Limits:
Humans
Language:
En
Journal:
Viruses
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: